Author Index: R
• AN INVESTIGATION OF ATTRIBUTE NON-ATTENDANCE IN CHOICE EXPERIMENTS CONTAINING DISEASE LABELS
• A COST-EFFECTIVENESS EVALUATION OF IBRUTINIB FOR PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN BRITISH COLUMBIA, CANADA
• PATIENT PREFERENCES FOR GENOMICS-BASED INDIVIDUALIZED HEALTHCARE: DEVELOPMENT OF A DISCRETE CHOICE EXPERIMENT INSTRUMENT ON PRECISION MEDICINE
• A COST-EFFECTIVENESS EVALUATION OF IBRUTINIB FOR PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN BRITISH COLUMBIA, CANADA
• PATIENT PREFERENCES FOR GENOMICS-BASED INDIVIDUALIZED HEALTHCARE: DEVELOPMENT OF A DISCRETE CHOICE EXPERIMENT INSTRUMENT ON PRECISION MEDICINE
• COMBINING A COLORECTAL CANCER SCREENING DECISION AID AND PATIENT NAVIGATION IMPROVES DECISION MAKING PROCESSES AND SCREENING COMPLETION IN LINGUISTICALLY DIVERSE PRIMARY CARE PATIENTS
• EFFECT OF A LUNG CANCER SCREENING DECISION AID ON KNOWLEDGE OF SCREENING HARMS AND SCREENING PREFERENCE IN PRIMARY CARE PATIENTS
• EFFECT OF A LUNG CANCER SCREENING DECISION AID ON KNOWLEDGE OF SCREENING HARMS AND SCREENING PREFERENCE IN PRIMARY CARE PATIENTS
• THE INFLUENCE OF RISK PRESENTATION FORMAT ON WILLINGNESS TO START A MEDICATION
• DO VISUAL DECISION AIDS HELP PATIENTS CORRECTLY DIFFERENTIATE BETWEEN A 2% VS A 0.2% RISK?
• MODELING THE GIST OF RISKS, BENEFITS, AND VALUES IN PATIENTS' WILLINGNESS TO START MEDICATIONS
• SYMPOSIUM: HOW CAN WE BEST PRESENT UNCERTAINTY THAT ACTIVATES PATIENTS TO MAKE INFORMED DECISIONS?
• COMPARING PHYSICIANS' AND PATIENTS' EXPECTATIONS FOR ANTIBIOTICS: A STUDY ACROSS MULTIPLE SAMPLES
• WHEN NUMERICAL DIFFERENCES DON'T MATTER: JUDGMENTS OF APPROXIMATELY EQUAL (≈) FOR BREAST-CANCER STATISTICS
• DO VISUAL DECISION AIDS HELP PATIENTS CORRECTLY DIFFERENTIATE BETWEEN A 2% VS A 0.2% RISK?
• MODELING THE GIST OF RISKS, BENEFITS, AND VALUES IN PATIENTS' WILLINGNESS TO START MEDICATIONS
• SYMPOSIUM: HOW CAN WE BEST PRESENT UNCERTAINTY THAT ACTIVATES PATIENTS TO MAKE INFORMED DECISIONS?
• COMPARING PHYSICIANS' AND PATIENTS' EXPECTATIONS FOR ANTIBIOTICS: A STUDY ACROSS MULTIPLE SAMPLES
• WHEN NUMERICAL DIFFERENCES DON'T MATTER: JUDGMENTS OF APPROXIMATELY EQUAL (≈) FOR BREAST-CANCER STATISTICS
• RESPONSIVENESS OF A BRIEF MEASURE OF SMOKERS' KNOWLEDGE OF LUNG CANCER SCREENING WITH LOW-DOSE COMPUTED TOMOGRAPHY
• ACCEPTABILITY AND EFFICACY OF A VIDEO-BASED PATIENT DECISION AID ABOUT LUNG CANCER SCREENING WITH LOW-DOSE COMPUTED TOMOGRAPHY
• PRIMARY CARE PHYSICIANS' LUNG CANCER SCREENING PRACTICES: COMPARISONS BEFORE AND AFTER THE CENTERS FOR MEDICARE & MEDICAID'S NATIONAL COVERAGE DETERMINATION
• PATIENT SELF-ADVOCACY IN DECISION MAKING RELATED TO POST-TREATMENT SURVEILLANCE FOR COLORECTAL CANCER
• ACCEPTABILITY AND EFFICACY OF A VIDEO-BASED PATIENT DECISION AID ABOUT LUNG CANCER SCREENING WITH LOW-DOSE COMPUTED TOMOGRAPHY
• PRIMARY CARE PHYSICIANS' LUNG CANCER SCREENING PRACTICES: COMPARISONS BEFORE AND AFTER THE CENTERS FOR MEDICARE & MEDICAID'S NATIONAL COVERAGE DETERMINATION
• PATIENT SELF-ADVOCACY IN DECISION MAKING RELATED TO POST-TREATMENT SURVEILLANCE FOR COLORECTAL CANCER
• PROBABILISTIC SENSITIVITY ANALYSIS IN MICROSIMULATION MODELS: FINDING THE RIGHT BALANCE
• HEPATITIS C TREATMENT IN UNITED STATES PRISONS PREVENTS TRANSMISSION IN SOCIETY
• ORAL ABSTRACTS: IMPROVING MODELING RESEARCH
• BARRIERS TO SELF-MANAGEMENT IN PATIENTS WITH DIABETES. WHAT MATTERS?
• THE NATURAL HISTORY OF PRESCRIPTION-OPIOID AND HEROIN EPIDEMIC IN THE US
• HEPATITIS C TREATMENT IN UNITED STATES PRISONS PREVENTS TRANSMISSION IN SOCIETY
• ORAL ABSTRACTS: IMPROVING MODELING RESEARCH
• BARRIERS TO SELF-MANAGEMENT IN PATIENTS WITH DIABETES. WHAT MATTERS?
• THE NATURAL HISTORY OF PRESCRIPTION-OPIOID AND HEROIN EPIDEMIC IN THE US
• EXAMINING THE IMPACT OF INTRACRANIAL HEMORRHAGE RELATIVE TO ISCHEMIC STROKE IN ANTICOAGULATED PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
• HOW MUCH IS IT WORTH TO PREVENT SHINGLES? USING COST-EFFECTIVENESS ANALYSIS TO DETERMINE VALUE-BASED PRICING OF A NEW HERPES ZOSTER VACCINE
• USING COST-EFFECTIVENESS ANALYSIS TO DETERMINE A THRESHOLD FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS
• HOW MUCH IS IT WORTH TO PREVENT SHINGLES? USING COST-EFFECTIVENESS ANALYSIS TO DETERMINE VALUE-BASED PRICING OF A NEW HERPES ZOSTER VACCINE
• USING COST-EFFECTIVENESS ANALYSIS TO DETERMINE A THRESHOLD FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS